Molecular structure of Pentoxifylline, CAS Number: 6493-05-6
Pentoxifylline (CAS 6493-05-6)
See product citations (3)
Alternate Names:
Trental; Oxpentifylline
Application:
Pentoxifylline is a non-selective phosphodiesterase inhibitor. Inhibits endotoxin-induced synthesis of TNF-α
CAS Number:
6493-05-6
Purity:
≥99%
Molecular Weight:
278.31
Molecular Formula:
C13H18N4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Pentoxifylline is a non-selective PDE (phosphodiesterase) inhibitor. Inhibits endotoxin-induced synthesis of tumor necrosis factor-a (TNF alpha). Pentoxifylline inhibits the adhesion of T cells to the b1 and b2 Integrin ligands VCAM-1 and ICAM-1. Also prevents the down-regulation of microsomal cytochrome P450 caused by lipopolysaccharides.This compound is also a PDE (phosphodiesterase) inhibitor that blocks production of TNF alpha and other cytokines. Displays antinociceptive activity.
Pentoxifylline (CAS 6493-05-6) References
- Pentoxifylline in preterm neonates: a systematic review. | Harris, E., et al. 2010. Paediatr Drugs. 12: 301-11. PMID: 20799759
- Pentoxifylline for intermittent claudication. | Salhiyyah, K., et al. 2012. Cochrane Database Syst Rev. 1: CD005262. PMID: 22258961
- Pentoxifylline use in dermatology. | Çakmak, SK., et al. 2012. Inflamm Allergy Drug Targets. 11: 422-32. PMID: 22680624
- Pentoxifylline in liver ischemia and reperfusion. | Genovés, P., et al. 2014. J Invest Surg. 27: 114-24. PMID: 24143911
- Pentoxifylline in heart failure: a meta-analysis of clinical trials. | Champion, S., et al. 2014. Cardiovasc Ther. 32: 159-62. PMID: 24758396
- Can Pentoxifylline be used as Adjunct Therapy to ACE Inhibitors and ARBs in Preserving Kidney Function? | Carson, C., et al. 2016. J Pharm Pharm Sci. 19: 1-7. PMID: 27096690
- Pentoxifylline - a review of its use in osteoradionecrosis. | Lyons, AJ. and Brennan, PA. 2017. Br J Oral Maxillofac Surg. 55: 230-234. PMID: 28034471
- Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. | Wen, WX., et al. 2017. Adv Ther. 34: 1245-1269. PMID: 28484954
- Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. | Hendry, BM., et al. 2020. Pharmacol Res Perspect. 8: e00631. PMID: 32715661
- Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant? | Bell, DSH. 2021. Diabetes Ther. 12: 3025-3035. PMID: 34647189
- Pentoxifylline in dermatology. | Balazic, E., et al. 2023. J Cosmet Dermatol. 22: 410-417. PMID: 36208009
- Pentoxifylline. | Samlaska, CP. and Winfield, EA. 1994. J Am Acad Dermatol. 30: 603-21. PMID: 8157787
- Pentoxifylline and skin inflammation. | Bruynzeel, I., et al. 1998. Clin Exp Dermatol. 23: 168-72. PMID: 9894361
Inhibitor of:
β-defensin 46, δ-sarcoglycan, cryptdin 21, GABAA Rα3, Macrophagee Marker, MK, Olfr1031, Olfr1065, Olfr509, Olr483, PDE, PDE6G, PDE8B, PED7A, PlGF, PR3, RADIL, Serine racemase, Tenr, TNF-IP 1, Tnfrsf26, and UT-A.Activator of:
1700011H22Rik, 2′-PDE, Arbp, ARMC4, CCDC85B, CINAP, Emi1, Gucy2g, HDHD2, IGFL1, IVNS1ABP, Keratin 31, Ksr-1, ODF3B, PDE5A, PDE6α, PKA IIα reg, PKAα cat, Podocin, PRODH2, Rad50, RAPGEF5, Rpp25, RSP3, SPAG1, SPAG16, SPESP1, TCP-11, TMEM25, Transketolase, TROY, utrophin, and Vmn1r77.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pentoxifylline, 1 g | sc-203184 | 1 g | $20.00 |